Regeneron Licenses CRISPR-Cas9 IP From ERS Genomics

Nov 24, 2015 | a GenomeWeb staff reporter

NEW YORK (GenomeWeb) – ERS Genomics today announced that it has non-exclusively licensed patents related to CRISPR-Cas9 genome-editing technology to Regeneron Pharmaceuticals for use in drug discovery and development.

Specific terms of the deal were not disclosed.

ERS was founded to provide broad access to the intellectual property, which is based on the research of Emmanuelle Charpentier from the Hannover Medical School in Germany and Umea University in Sweden.

"Genome editing has many applications in drug discovery and development and making the CRISPR-Cas9 patents widely available to biotechnology and pharmaceutical companies is an important part of ERS Genomics' strategy," ERS CEO and Founder Shaun Foy said in a statement.

Last year, ERS signed an agreement providing non-exclusive access to the IP to Horizon Discovery for research applications.

Filed Under Business News | Gene Silencing/Gene Editing | licensing agreement | CRISPR | Regeneron

Related Articles

Apr 12, 2016

Intellia Files for $120M IPO, Inks Lucrative Collaboration With Regeneron

Jul 06, 2016

Evotec Licenses CRISPR Tech From Broad Institute, Harvard

Sep 22, 2016
Monsanto Licenses CRISPR From Broad Institute for Ag-Bio Applications

May 02, 2016
Geisinger MyCode Results, Reengagement of Patients May Clarify Variant Pathogenicity, Penetrance ■

Jun 27, 2016
Regeneron, Scandanavian Schools to Study Genetics of Diabetes

Mar 03, 2016
Teams Describe Mutations Tied to Lower Triglyceride Levels, Reduced Coronary Artery Disease Risk

We recommend

Horizon Expands CRISPR-Cas9 Portfolio with Broad Institute Licensing Deal
GenomeWeb, 2014

Caribou Bio Grants IDT Non-Exclusive Rights to Commercialize RUO CRISPR/Cas9 Reagents
GenomeWeb, 2016

Monsanto Licenses CRISPR From Broad Institute for Ag-Bio Applications
GenomeWeb, 2016

DuPont, Caribou Biosciences Ink Strategic Alliance on CRISPR, Cross-License IP
GenomeWeb, 2015

Broad Licenses CRISPR/Cas9 IP to GE Healthcare, Sigma-Aldrich
GenomeWeb, 2014

Broad Institute Licenses CRISPR/Cas9 IP to Transposagen
GenomeWeb, 2015

Powered by TrendMD

Privacy Policy. Copyright © 2016 Genomeweb LLC. All Rights Reserved.